Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
Healthcare
$22.71 -10.03%
-$3.24 today
- Market cap
- $3.85B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
52W Low $4.60High $34.39
Volume 1.81M
Average 3.67M
Income Statement
Follow revenue through to earnings.
Revenue
$62.38M
FY 2025 · Annual
+48.3% YoYOperating Income
-$111.29M
FY 2025 · Annual
Net Income
-$101.59M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.04M | 24.86M | 36.53M | 42.07M | 62.38M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.28M |
| Gross Profit | 37.04M | 24.86M | 36.53M | 42.07M | 60.1M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.3% |
| Research & Development | 77.64M | 105.91M | 115.2M | 143.92M | 132.17M |
| Selling, General & Admin | 17.6M | 30.03M | 35.5M | 43.75M | 41.51M |
| Operating Expenses | 95.23M | 135.93M | 150.7M | 187.66M | 171.39M |
| Depreciation & Amortization | 897K | 1.61M | 2.42M | 2.5M | 2.28M |
| EBITDA | (57.05M) | (106.51M) | (99.2M) | (127.6M) | (99.31M) |
| EBITDA Margin | -154.0% | -428.5% | -271.6% | -303.3% | -159.2% |
| Operating Income | (58.19M) | (111.07M) | (114.17M) | (145.6M) | (111.29M) |
| Operating Margin | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| Interest Income | 495K | 1.46M | 6.62M | 7.89M | 5.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 247K | 2.95M | 12.56M | 15.5M | 9.7M |
| Income Before Tax | (57.94M) | (108.12M) | (101.61M) | (130.09M) | (101.59M) |
| Pre-Tax Margin | -156.4% | -434.9% | -278.2% | -309.2% | -162.8% |
| Income Tax Expense | 292K | 54K | 134K | 208K | 4K |
| Net Income | (58.24M) | (108.18M) | (101.74M) | (130.3M) | (101.59M) |
| Net Margin | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
| EPS (Basic) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
| EPS (Diluted) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
| 62.11M | 87.82M | 94.57M | 109.23M | 116.17M | |
| 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
TNGX Earnings Waterfall · TTM
NASDAQ:TNGX · Revenue to Net Income
Key Ratios
EPS$-1.38
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-15.2
P/S Ratio0.0
Analysis
$0 of revenue converted into -$208.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.38, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 |
How much revenue does TNGX generate?
Tango Therapeutics, Inc. (TNGX) reported $62.38M of revenue in fiscal 2025.
Is TNGX profitable?
Tango Therapeutics, Inc. (TNGX) reported -$101.59M of net income, with a net margin of -162.9%.
Continue the stock analysis
Jump to another research area for this company.